15.81

5.05% -0.84

After Hours: 16.01 0.20 +1.27%

Viridian Therapeutics Inc (VRDN)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Viridian Therapeutics Inc stock is traded at $15.81, with a volume of 503.42K. It is down -5.05% in the last 24 hours and down -7.11% over the past month. Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Previous Close:

$16.65

Open:

$16.54

24h Volume:

503.42K

Relative Volume:

0.41

Market Cap:

$1.29B

Revenue:

$288.00K

Net Income/Loss:

$-228.06M

P/E Ratio:

-3.72

EPS:

-4.25

Net Cash Flow:

$-168.82M

1W Performance:

-0.44%

1M Performance:

-7.11%

6M Performance:

-28.33%

1Y Performance:

-11.23%

1-Day Range:

$15.78

$16.74

1-Week Range:

$14.97

$17.00

52-Week Range:

$11.40

$27.20

Viridian Therapeutics Inc Stock (VRDN) Company Profile

Name

Viridian Therapeutics Inc

Sector

Healthcare (1169)

Industry

Biotechnology (679)

Phone

617.272.4600

Address

221 CRESCENT STREET, WALTHAM

Employee

143

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

VRDN's Discussions on Twitter

Compare VRDN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VRDN Viridian Therapeutics Inc	15.81	1.29B	288.00K	-228.06M	-168.82M	-4.25
VRTX Vertex Pharmaceuticals Inc	502.92	129.14B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	680.61	74.41B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	581.21	35.31B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.75	31.30B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	254.57	27.35B	3.32B	-860.46M	-1.04B	-8.32

Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-25-24	Initiated	TD Cowen	Buy
Sep-11-24	Reiterated	Needham	Buy
Jun-11-24	Initiated	Wolfe Research	Outperform
Jun-06-24	Initiated	Goldman	Buy
May-09-24	Downgrade	B. Riley Securities	Buy → Neutral
May-09-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
Jun-14-23	Initiated	BTIG Research	Buy
Jun-14-23	Resumed	Credit Suisse	Outperform
May-30-23	Initiated	RBC Capital Mkts	Outperform
Apr-17-23	Initiated	Wells Fargo	Overweight
Mar-30-23	Initiated	Stifel	Buy
Dec-19-22	Initiated	Cowen	Outperform
Dec-19-22	Initiated	Needham	Buy
Dec-16-22	Initiated	Credit Suisse	Outperform
Dec-01-22	Initiated	H.C. Wainwright	Buy
Jun-23-22	Initiated	B. Riley Securities	Buy
Nov-18-21	Initiated	SVB Leerink	Outperform
Oct-12-21	Initiated	Evercore ISI	Outperform
Jan-25-21	Initiated	Ladenburg Thalmann	Buy

View All

Viridian Therapeutics Inc Stock (VRDN) Latest News

Mar 12, 2025

Viridian Therapeutics at Leerink’s Conference: Progress in TED Treatments By Investing.com - Investing.com UK

Mar 12, 2025

Mar 10, 2025

Viridian Therapeutics Announces Inducement Stock Option Grants - Nasdaq

Mar 10, 2025

Viridian Therapeutics appoints new director, sees board resignation - Investing.com India

Mar 10, 2025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bluefield Daily Telegraph

Mar 10, 2025

Viridian Therapeutics Appoints Radhika Tripuraneni as Chief Medical Officer - StockTitan

Mar 10, 2025

Mar 06, 2025

What is B. Riley’s Forecast for VRDN Q1 Earnings? - Defense World

Mar 06, 2025

Mar 05, 2025

Principal Financial Group Inc. Has $3.42 Million Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Mar 05, 2025

What is B. Riley’s Estimate for VRDN Q2 Earnings? - Defense World

Mar 05, 2025

Mar 04, 2025

Decoding Viridian Therapeutics Inc (VRDN): A Strategic SWOT Insi - GuruFocus.com

Mar 04, 2025

Viridian Therapeutics inks new $300M sales agreement By Investing.com - Investing.com South Africa

Mar 04, 2025

Viridian Therapeutics Terminates Prior $175 Million Sale Agreement -March 04, 2025 at 06:36 am EST - Marketscreener.com

Mar 04, 2025

Viridian Therapeutics Enters New $300M Sale Agreement - TipRanks

Mar 04, 2025

Viridian Therapeutics inks new $300M sales agreement - Investing.com

Mar 04, 2025

Rhumbline Advisers Has $1.92 Million Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Mar 04, 2025

Viridian Therapeutics Faces Uncertainty Amid Regulatory Approval Challenges - TipRanks

Mar 04, 2025

Mar 03, 2025

Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window - Seeking Alpha

Mar 02, 2025

FY2027 EPS Forecast for Viridian Therapeutics Cut by Analyst - Defense World

Mar 02, 2025

Feb 28, 2025

Viridian Therapeutics (NASDAQ:VRDN) Posts Earnings Results, Beats Expectations By $0.24 EPS - MarketBeat

Feb 28, 2025

RBC Capital Adjusts Viridian Therapeutics Price Target to $46 From $47, Maintains OutperformSpeculative Risk Rating - Marketscreener.com

Feb 28, 2025

Viridian Therapeutics: Promising Market Position and Growth Prospects Justify Buy Rating - TipRanks

Feb 28, 2025

Viridian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Feb 28, 2025

Viridian Therapeutics Reports Strong Progress and Financials - TipRanks

Feb 28, 2025

Feb 27, 2025

Viridian Therapeutics: Strong Financials and Promising Clinical Developments Drive Buy Rating - TipRanks

Feb 27, 2025